NCT07079046: Satisens

Efficacy of Satisens® in Reducing Emotional Eating

Not yet recruiting NA Last updated 18 July 2025

What this trial tests

NA trial testing Intervention 1: Satisens® in Emotional Eating in 84 participants. Not yet recruiting.

Timeline

1 July 2025

Primary endpoint
1 January 2026

1 June 2026

Quick facts

Lead sponsor	José Enrique de la Rubia Ortí, Ph
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	84
Start date	1 July 2025
Primary completion	1 January 2026
Estimated completion	1 June 2026
Sites	1 location across Spain

Drugs / interventions tested

• Intervention 1: Satisens®
• Intervention 2: Placebo — full drug profile →

Conditions studied

• Emotional Eating — all drugs for Emotional Eating →
• Overweight or Obesity — all drugs for Overweight or Obesity →
• Hormonal Changes — all drugs for Hormonal Changes →
• Neurotransmitter Agents — all drugs for Neurotransmitter Agents →

Sponsor

José Enrique de la Rubia Ortí, Ph

Who can join

Adults 18 to 65, any sex, with Emotional Eating or Overweight or Obesity. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• Change in Emotional Eating Score (EEQ)
  Time frame: Baseline, Week 8, Week 12
  Measured using the Emotional Eating Questionnaire (EEQ) to assess changes in emotional eating behavior. Scale Range: 0 to 30 Interpretation: Higher scores indicate worse emotional eating behavior (i.e., greater tendency to eat in response to emotions).
• Change in Appetite Score (VAS)
  Time frame: Baseline, Week 8, Week 12
  Visual Analog Scale adapted for appetite, including hunger, satiety, fullness, and prospective food consumption. Scale Range: 0 to 100 for each item Interpretation: Higher scores indicate greater satiety and lower appetite. Therefore, a higher PA score reflects a better outcome in terms of appetite control.
• Change in Sweet Craving (PFS)
  Time frame: Baseline, Week 8, Week 12
  Power of Food Scale adapted to sweet foods to assess psychological craving. Scale Range: 1 to 5 per item (typically 15 items total; total score range: 15 to 75) Interpretation: Higher scores indicate greater psychological craving for sweet foods, thus a worse outcome in the context of this study.
• Change in Body Weight
  Time frame: Baseline, Week 8, Week 12
  Measured in kilograms (kg) using a calibrated scale with participants in a fasting state. Unit of Measure: Kilograms (kg) Interpretation: A decrease in weight indicates a better outcome.
• Change in Body Mass Index (BMI)
  Time frame: Baseline, Week 8, Week 12
  Calculated as weight (kg) divided by height squared (m²). Unit of Measure: kg/m² Interpretation: A decrease in BMI indicates a better outcome.
• Change in Waist Circumference
  Time frame: Baseline, Week 8, Week 12
  Measured in centimeters (cm) at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest. Unit of Measure: Centimeters (cm) Interpretation: A decrease in waist circumference indicates a better outcome.

Sponsor's own description

This study evaluates the efficacy of Satisens®, a dietary supplement composed of plant extracts, in reducing emotional eating and sweet cravings in healthy adults. The study will analyze hormonal, neurotransmitter, and inflammatory markers to understand the underlying mechanisms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.